Delaware
|
001-37752
|
26-2940963
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
Title
of each class
|
Trading
Symbol(s)
|
Name of
each exchange on which registered
|
Common
Stock, par value $0.001 per share
|
CDXC
|
The
Nasdaq Capital Market
|
Patent Number
|
Title
|
Filing Date
|
Issued Date
|
Expires
|
Licensor
|
7,205,284
|
Potent
immunostimulants from microalgae
|
7/10/2001
|
4/17/2007
|
3/9/2022
|
Licensed
from University of Mississippi
|
7,776,326
|
Methods
and compositions for treating neuropathies
|
6/3/2005
|
8/17/2010
|
6/24/2026
|
Licensed
from Washington University
|
7,846,452
|
Potent
immunostimulatory extracts from microalgae
|
7/28/2005
|
12/7/2010
|
7/28/2025
|
Licensed
from University of Mississippi
|
8,106,184
|
Nicotinyl
Riboside Compositions and Methods of Use
|
11/17/2006
|
1/31/2012
|
9/20/2027
|
Licensed
from Cornell University
|
8,114,626
|
Yeast
strain and method for using the same to produce Nicotinamide
Riboside
|
3/26/2009
|
2/14/2012
|
1/5/2026
|
Licensed
from Dartmouth College
|
8,133,917
|
Pterostilbene
as an agonist for the peroxisome proliferator-activated receptor
alpha isoform
|
10/25/2010
|
3/13/2012
|
8/18/2025
|
Licensed
from the University of Mississippi and U.S. Department of
Agriculture
|
8,197,807
|
Nicotinamide
Riboside Kinase compositions and Methods for using the
same
|
4/20/2006
|
6/12/2012
|
11/19/2026
|
Licensed
from Dartmouth College
|
8,252,845
|
Pterostilbene
as an agonist for the peroxisome proliferator-activated receptor
alpha isoform
|
2/1/2012
|
8/28/2012
|
8/18/2025
|
Licensed
from the University of Mississippi and U.S. Department of
Agriculture
|
8,318,807
|
Pterostilbene
Caffeine Co-Crystal Forms
|
7/30/2010
|
11/27/2012
|
7/21/2031
|
Licensed
from Laurus Labs Private Limited
|
8,383,086
|
Nicotinamide
Riboside Kinase compositions and Methods for using the
same
|
4/12/2012
|
2/26/2013
|
4/20/2026
|
Licensed
from Dartmouth College
|
8,399,712
|
Pterostilbene
cocrystals
|
7/30/2010
|
3/19/2013
|
8/10/2031
|
Licensed
from Laurus Labs Private Limited
|
8,524,782
|
Key
intermediate for the preparation of Stilbenes, solid forms of
Pterostilbene, and methods for making the same
|
1/21/2011
|
9/3/2013
|
2/1/2030
|
Licensed
from Laurus Labs Private Limited
|
8,809,400
|
Method
to Ameliorate Oxidative Stress and Improve Working Memory Via
Pterostilbene Administration
|
8/8/2011
|
8/19/2014
|
10/2/2028
|
Licensed
from the University of Mississippi and U.S. Department of
Agriculture
|
8,841,350
|
Method
for treating non-melanoma skin cancer by inducing
UDP-Glucuronosyltransferase activity using
pterostilbene
|
5/8/2012
|
9/23/2014
|
5/8/2032
|
Co-owned
by ChromaDex and University of California
|
8,889,126
|
Methods
and compositions for treating neuropathies
|
5/28/2010
|
11/18/2014
|
6/3/2025
|
Licensed
from Washington University
|
9,000,147
|
Nicotyl
riboside compositions and methods of use
|
1/17/2012
|
4/7/2015
|
11/17/2026
|
Licensed
from Cornell University
|
9,028,887
|
Method
improve spatial memory via pterostilbene
administration
|
5/22/2014
|
5/12/2015
|
6/10/2028
|
Licensed
from the University of Mississippi and U.S. Department of
Agriculture
|
9,295,688
|
Methods
and compositions for treating neuropathies
|
10/10/2014
|
3/29/2016
|
6/3/2025
|
Licensed
from Washington University
|
9,321,797
|
Nicotyl
riboside compositions and methods of use
|
11/17/2014
|
4/26/2016
|
11/17/2026
|
Licensed
from Cornell University
|
9,439,875
|
Anxiolytic
effect of pterostilbene
|
5/11/2011
|
9/13/2016
|
12/11/2031
|
Licensed
from the University of Mississippi and U.S. Department of
Agriculture
|
9,975,915
|
Crystalline
forms of nicotinoyl ribosides, modified derivatives thereof, and
phosphorylated analogs thereof, and methods of preparation
thereof
|
11/10/2017
|
5/22/2018
|
11/10/2037
|
Co-owned
by ChromaDex and The Queen’s University of
Belfast
|
10,000,519
|
Methods of Preparing Nicotinamide Riboside and Derivatives
Thereof
|
7/24/2014
|
6/19/2018
|
7/24/2034
|
Licensed from The Queen’s University of
Belfast
|
10,000,520
|
B-vitamin
and amino acid conjugates ofnicotinoyl ribosides and reduced
nicotinoyl ribosides, derivatives thereof, and methods of
preparation thereof
|
3/16/2017
|
6/19/2018
|
3/16/2037
|
Co-owned
by ChromaDex and The Queen’s University of
Belfast
|
10,183,036
|
Use of nicotinic acid riboside or nicotinamide riboside
derivatives, and reduced derivatives thereof, as NAD+ increasing
precursors
|
4/20/2017
|
1/22/2019
|
4/20/2037
|
Owned by ChromaDex
|
10,280,190
|
Nicotinic acid riboside or nicotinamide riboside compositions,
reduced derivatives thereof, and the use thereof to enhance skin
permeation in treating skin conditions
|
3/16/2016
|
5/7/2019
|
5/31/2036
|
Co-owned by ChromaDex and The Queen’s University of
Belfast
|
10,688,118
|
Nicotinamide riboside compositions for topical use in treating skin
conditions
|
10/30/2014
|
6/23/2020
|
4/6/2035
|
Owned by ChromaDex
|
10,689,411
|
Efficient and scalable syntheses of nicotinoyl ribosides and
reduced nicotinoyl ribosides, modified derivatives thereof,
phosphorylated analogs thereof, adenylyl dinucleotide conjugates
thereof, and novel crystalline forms
thereof
|
11/10/2017
|
6/23/2020
|
11/10/2037
|
Co-owned by ChromaDex and The Queen’s University of
Belfast
|
|
|
|
|
|
|
|
|
|
|
|
CHROMADEX CORPORATION
|
||
|
|
|
||||
Dated:
July 8, 2020
|
|
|
|
|
||
|
|
|
|
|||
|
|
|
|
By:
|
|
/s/
Kevin M.
Farr
|
|
|
|
|
|
|
Name:
Kevin M. Farr
|
|
|
|
|
|
|
Chief
Financial Officer
|